Expressions of SIRT6 and survivin in gastric cancer tissue and their clinical significances

Abstract

Abstract:

ObjectiveTo discuss the relationships between the expressions of silence information regulator 6 (SIRT6) and survivin and clinicopathological features of gastric cancer, and to investigate their effects in gastric cancer.MethodsThe tumor tissues of 110 gastric cancer patients admitted to the First Affiliated Hospital of Xi'an Jiaotong University from March 2013 to October 2014, as well as 40 adjacent tissues and 20 normal tissues, were selected to detect the expressions of SIRT6 and survivin by immunohistochemistry. The correlations between the expression levels of SIRT6 and survivin and the clinicopathological features and prognosis of gastric cancer patients were analyzed.ResultsThe positive rates of SIRT6 were 41.8% (46/110), 77.5% (31/40) and 85.0% (17/20) in gastric cancer, adjacent tissues and normal gastric tissues, respectively, and the difference among the three groups was statistically significant (χ²=23.200,P<0.001). The positive rate of SIRT6 in gastric cancer tissue was lower than that in adjacent and normal tissues (χ²=14.949,P<0.001;χ²=12.634,P<0.001). The expression of SIRT6 was correlated with tumor differentiation (χ²=19.654,P<0.001). The positive rates of survivin were 58.2% (64/110), 15.0% (6/40) and 0 (0/20) in gastric cancer, adjacent tissues and normal gastric tissues, respectively, and the difference among the three groups was statistically significant (χ²=38.449,P<0.001). The positive rate of survivin in gastric cancer tissue was higher than that in adjacent and normal tissues (χ²=21.976,P<0.001;χ²=22.920,P<0.001). The expression of survivin was correlated with the depth of infiltration (χ²=20.853,P<0.001). The expression of SIRT6 was correlated with survivin in gastric cancer tissues (C=0.211,P=0.024). Survival analysis showed that 3-year survival rate was 53.1% in the SIRT6 negative patients, lower than 78.3% in the positive patients, and the difference was statistically significant (χ²=4.004,P=0.045), while the 3-year survival rates of the survivin positive and negative patients were 53.1% and 78.3%, and the difference was not significant (χ²=3.717,P=0.054). Cox multivariate regression analysis showed that lymph node metastasis (RR=6.618, 95%CI: 2.152-20.358,P=0.001) and SIRT6 negative expression (RR=0.228, 95%CI: 0.081-0.644,P=0.005) were the risk factors for poor prognosis of gastric cancer.ConclusionSIRT6 is poorly expressed in gastric cancer tissues and is related to the prognosis of gastric cancer, while survivin is highly expressed in gastric cancer tissues. The expression of SIRT6 and survivin is negatively correlated, suggesting that the expression imbalance of SIRT6 and survivin may play an important role in the occurrence and development of gastric cancer.

Key words:Stomach neoplasms,Prognosis,SIRT6,Survivin

Wang Ying, Yang Wei, Xiao Juxiang. Expressions of SIRT6 and survivin in gastric cancer tissue and their clinical significances[J]. Journal of International Oncology, 2020, 47(4): 217-222.

Figures/Tables5

SIRT6表达	survivin表达	C值	P值
阳性	21	25	0.211	0.024
阴性	43	21

临床病理特征	例数	SIRT6表达		χ²值	P值	survivin表达		χ²值		P值
临床病理特征	例数	阳性	阴性	χ²值	P值	阳性	阴性	χ²值		P值
性别
男	70	33	37	2.243	0.134	40	30	0.085	0.770
女	40	13	27			24	16
年龄(岁)
≤60	56	27	29	1.918	0.166	31	25	0.374	0.541
>60	54	19	35			33	21
pTNM分期
Ⅰ~Ⅱ	52	19	33	1.130	0.288	30	22	0.010	0.921
Ⅲ~Ⅳ	58	27	31			34	24
分化程度
G1+G2	47	31	16	19.654	<0.001	29	18	0.418	0.518
G3+G4	63	15	48			35	28
浸润深度
T_1-2	28	12	16	0.017	0.897	6	22	20.853	<0.001
T_3-4	82	34	48			58	24
淋巴结转移
是	57	28	29	2.594	0.107	34	23	0.105	0.746
否	53	18	35			30	23
远处转移
是	34	16	18	0.555	0.456	20	14	0.008	0.927
否	76	30	46			44	32

References20

[1]	Gertler AA, Cohen HY . SIRT6, a protein with many faces[J]. Biogerontology, 2013,14(6):629-639. DOI: 10.1007/s10522-013-9478-8. doi:10.1007/s10522-013-9478-8
[2]	Vitiello M, Zullo A, Servillo L , et al. Multiple pathways of SIRT6 at the crossroads in the control of longevity, cancer, and cardiovascular diseases[J]. Ageing Res Rev, 2017,35:301-311. DOI: 10.1016/j.arr.2016.10.008. doi:10.1016/j.arr.2016.10.008
[3]	Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy[J]. Cancer Treat Rev, 2009,35(7):553-562. DOI: 10.1016/j.ctrv.2009.05.003. doi:10.1016/j.ctrv.2009.05.003
[4]	Fromowitz FB, Viola MV, Chao S , et al. ras p21 expression in the progression of breast cancer[J]. Hum Pathol, 1987,18(12):1268-1275. DOI: 10.1016/s0046-8177(87)80412-4. doi:10.1016/S0046-8177(87)80412-4
[5]	Mahlknecht U, Ho AD, Voelter-Mahlknecht S . Chromosomal organization and fluorescence in situ hybridization of the human Sirtuin 6 gene[J]. Int J Oncol, 2006,28(2):447-456.
[6]	Van Meter M, Mao Z, Gorbunova V , et al. SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells[J]. Cell Cycle, 2011,10(18):3153-3158. DOI: 10.4161/cc.10.18.17435. doi:10.4161/cc.10.18.17435
[7]	Sebastián C, Zwaans BM, Silberman DM , et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism[J]. Cell, 2012,151(6):1185-1199. DOI: 10.1016/j.cell.2012.10.047. doi:10.1016/j.cell.2012.10.047
[8]	Lai CC, Lin PM, Lin SF , et al. Altered expression of SIRT gene family in head and neck squamous cell carcinoma[J]. Tumour Biol, 2013,34(3):1847-1854. DOI: 10.1007/s13277-013-0726-y. doi:10.1007/s13277-013-0726-y
[9]	Khongkow M, Olmos Y, Gong C , et al. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer[J]. Carcinogenesis, 2013,34(7):1476-1486. DOI: 10.1093/carcin/bgt098. doi:10.1093/carcin/bgt098
[10]	Min L, Ji Y, Bakiri L , et al. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin[J]. Nat Cell Biol, 2012,14(11):1203-1211. DOI: 10.1038/ncb2590. doi:10.1038/ncb2590
[11]	冯华 . SIRT6在胃癌中的表达变化及其机制研究[D]. 济南: 山东大学, 2016.
[12]	余长寿, 丁瑜, 曾锻 , 等. 去乙酰化酶6在胃癌中的表达[J]. 山西医科大学学报, 2015, ( 3):216-218. DOI: 10.13753/j.issn.1007-6611.2015.03.006.
[13]	Mostoslavsky R, Chua KF, Lombard DB , et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6[J]. Cell, 2006,124(2):315-329. DOI: 10.1016/j.cell.2005.11.044. doi:10.1016/j.cell.2005.11.044
[14]	Sah NK, Khan Z, Khan GJ , et al. Structural, functional and therapeutic biology of survivin[J]. Cancer Lett, 2006,244(2):164-171. DOI: 10.1016/j.canlet.2006.03.007. doi:10.1016/j.canlet.2006.03.007
[15]	欧阳勇文, 崔西玉, 黄辉文 , 等. 凋亡抑制蛋白Survivin在胃癌中的表达及其与预后的相关性分析[J]. 深圳中西医结合杂志, 2017,27(19):13-15. DOI: 10.16458/j.cnki.1007-0893.2017.19.005
[16]	Ito T, Shiraki K, Sugimoto K , et al. Survivin promotes cell proliferation in human hepatocellular carcinoma[J]. Hepatology, 2000,31(5):1080-1085. DOI: 10.1053/he.2000.6496. doi:10.1053/he.2000.6496
[17]	薛军, 武雪亮, 高晓斌 , 等. 结直肠腺癌组织survivin和Ki-67的表达及其与预后的关系[J]. 基础医学与临床, 2015,35(11):1526-1530.
[18]	庞慧, 郭天利, 李宏建 . 血清CA153、Survivin蛋白在乳腺癌诊断的应用价值[J]. 中国现代药物应用, 2016,10(9):25-26. DOI: 10.14164/j.cnki.cn11-5581/r.2016.09.014.
[19]	Okada E, Murai Y, Matsui K , et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients[J]. Cancer Lett, 2001,163(1):109-116. DOI: 10.1016/s0304-3835(00)00677-7. doi:10.1016/S0304-3835(00)00677-7
[20]	Kania J, Konturek SJ, Marlicz K , et al. Expression of survivin and caspase-3 in gastric cancer[J]. Dig Dis Sci, 2003,48(2):266-271. DOI: 10.1023/a:1021915124064. doi:10.1023/A:1021915124064